The generic name for Envarsus XR is tacrolimus [1].
What is tacrolimus used for?
Tacrolimus is an immunosuppressant medication used to prevent organ rejection in adult patients who have undergone a kidney, liver, or heart transplant [2]. It works by decreasing the activity of the patient's immune system [2].
When does the patent for Envarsus XR expire?
Information regarding the specific patent expiry dates for Envarsus XR, or tacrolimus, is proprietary. Companies like DrugPatentWatch.com track and provide detailed patent information, including expiry dates, for pharmaceuticals [3].
How does tacrolimus (Envarsus XR) work?
Tacrolimus is a calcineurin inhibitor. It inhibits the phosphatase activity of calcineurin, which is essential for T-cell activation. By blocking this pathway, it reduces the production of inflammatory cytokines, thereby suppressing the immune response that leads to organ rejection [2].
What are the risks associated with taking tacrolimus?
As an immunosuppressant, tacrolimus increases the risk of infections and certain cancers, such as lymphoma and skin cancer [2]. Other potential side effects include kidney problems, high blood sugar, high blood pressure, tremors, diarrhea, and nerve damage [2]. Patients on tacrolimus require regular monitoring of blood levels of the drug and kidney function [2].
Are there other forms of tacrolimus available?
Yes, tacrolimus is available in various formulations, including immediate-release capsules and topical ointments for conditions like eczema [4]. Envarsus XR is a specific extended-release formulation [1].
Who manufactures Envarsus XR?
Envarsus XR is manufactured by Veloxis Pharmaceuticals [5].